Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

PhotoCure ASA Presents New Meta-Analysis Confirming Clinical Benefit of Hexvix-Guided Blue Light Cystoscopy


Monday, 18 Mar 2013 03:55am EDT 

PhotoCure ASA announced that a new meta-analysis confirming the clinical benefit of Hexvix-guided blue light cystoscopy for patients with known or suspected non-muscle invasive bladder cancer, was presented at the 28th Annual European Association of Urology (EAU) Congress in Milan on March 17, 2013. Hexvix is Photocure's product to aid in the diagnosis and management of bladder cancer. The meta-analysis, which was conducted on raw data from eight Hexvix prospective studies and included a total of 1,293 patients, confirms previous studies and indicates that Hexvix cystoscopy significantly improves the detection of bladder cancer and reduces the risk of recurrence.